CoronavirusFeaturedLatest News

CDC issues temporary halt to Johnson & Johnson COVID-19 vaccine

UPDATE 6:44 PM April 13, 2021: According to the Washington state Department of Health, about 160,000 doses of J & J vaccine have been administered in Washington state.

April 13, 2021 – Today, the Centers for Disease Control and Prevention and the Food and Drug Administration announced a “pause” in using the single-dose Johnson & Johnson COVID-19 vaccine following six reported U.S. cases of a rare and severe type of blood clot.

Just two weeks ago nearly 15 million doses of Johnson & Johnson vaccine were ruined at a manufacturing plant in Baltimore.

Joint Media Call: FDA & CDC to Discuss J&J COVID-19 Vaccine – 4/13/2021

Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine

As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine.

In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given.

CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.

Right now, these adverse events appear to be extremely rare. COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at

CDC and FDA will provide additional information and answer questions later today at a media briefing. A recordingExternal Link Disclaimer of that media call is available on the FDA’s YouTube channel.

Content Source: Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine | FDA

The above statement is attributed to Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research and Dr. Anne Schuchat, Principal Deputy Director of the CDC.

Leave a Reply

Your email address will not be published. Required fields are marked *